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Abstract
Background: The glaucomas are a common but incompletely understood group of diseases. DBA/
2J mice develop a pigment liberating iris disease that ultimately causes elevated intraocular pressure
(IOP) and glaucoma. We have shown previously that mutations in two genes, Gpnmb and Tyrp1,
initiate the iris disease. However, mechanisms involved in the subsequent IOP elevation and optic
nerve degeneration remain unclear.
Results: Here we present new mouse strains with Gpnmb and/or Tyrp1 genes of normal function
and with a DBA/2J genetic background. These strains do not develop elevated IOP or glaucoma
with age.
Conclusion: These strains provide much needed controls for studying pathogenic mechanisms of
glaucoma using DBA/2J mice. Given the involvement of Gpnmb and/or Tyrp1 in areas such as
immunology and tumor development and progression, these strains are also important in other
research fields.
Background
Glaucomas are heterogeneous diseases that affect 70 mil-
lion people worldwide [1]. They are characterized by the
loss of retinal ganglion cells and degeneration of the optic
nerve [2,3]. Glaucoma is often associated with an age-
related elevation of intraocular pressure (IOP) [4]. Ele-
vated IOP induces glaucomatous neurodegeneration in
susceptible individuals. IOP elevation involves compro-
mised drainage of aqueous humor (AqH) through the
ocular drainage structures in the iridocorneal angle
(angle) [5]. Nevertheless, the molecular etiology of IOP
elevation varies between individuals and with the type of
glaucoma. In pigmentary glaucoma, the iris is damaged
resulting in dispersal of iris pigment and debris into the
anterior chamber and AqH drainage structures. In suscep-
tible individuals, the pigment and/or debris induces a
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process(es) that damages the drainage structures resulting
in high IOP and subsequent glaucoma [6-8]. DBA/2J (D2)
mice inherit a disease with similarities to human pigmen-
tary glaucoma [9,10], including ultrastructurally abnor-
mal melanosomes [11]. Around 5–6 months of age, D2
mice develop a pigment dispersing iris disease. Pigment
and/or iris debris induces drainage structure damage that
disrupts the outflow of aqueous humor. This causes an
elevation of IOP that first occurs in a significant portion of
mice around 8–9 months of age [10]. In our colony, about
70% of D2 mice develop moderate or severe glaucoma by
12 months of age [10]. There are now a number of inde-
pendent reports on DBA/2 glaucoma including several
recent ones (e.g. [10,12-14]). Some but not all of these
reports suggest earlier onset damage than we have
reported. This earlier onset damage clearly does not occur
in our colony as we have studied large numbers of mice
[10]. We have previously discussed possible explanations
for these differences including the exact substrain used
and environmental differences.
We have previously shown that the D2 iris disease is
genetically separable into two distinct traits, iris pigment
dispersion (IPD) and iris stromal atrophy (ISA) [15]. IPD
is characterized by a breakdown of the posterior iris pig-
ment epithelium, slit-like transillumination and promi-
nent pigment dispersion. IPD is caused by a mutation in
the glycoprotein (transmembrane) nmb gene
(GpnmbR150X), a recent mutation that arose on D2 in the
early 1980's [10,16]. ISA is characterized by deterioration
of the iris stroma, and an accumulation of stromal pig-
ment and cell debris in the drainage structures [15], and is
caused by a recessive mutation in the tyrosinase related
protein 1 gene (Tyrp1b) [16]. D2 mice are homozygous for
both GpnmbR150X and Tyrp1b mutations and inherit a much
more severe iris disease and subsequent glaucoma than
mice carrying either of the two mutations alone [16]. The
published characterization of both IPD and ISA was nec-
essarily performed using mice of a mixed genetic back-
ground when mapping and identifying the genes that
underlie these traits. These phenotypes have never been
fully analyzed in the context of a D2 genetic background.
D2 is one of the most widely used mouse strains in glau-
coma research. Here, we describe the development of
novel strains that can be used in conjunction with D2 to
further our understanding of the complex mechanisms
involved in pigment dispersing iris disease, IOP elevation
and glaucoma. Prior to developing these strains, there
were no control, age and strain-matched DBA/2J mice that
did not develop these phenotypes. Control D2.B6-
Tyrp1B6GpnmbB6/Sj mice (hereafter referred to as
D2.Tyrp1B6GpnmbB6) are homozygous for wild type alleles
of Tyrp1 and Gpnmb that are derived from strain C57BL/6J
(B6). These mice do not develop any iris disease, IOP ele-
vation or glaucoma. DBA/2J-Gpnmb+/Sj mice (hereafter
referred to as D2-Gpnmb+) are homozygous for a wild-type
allele of Gpnmb on a D2 genetic background. This Gpnmb+
allele is the original D2 allele that predates the R150X
mutation (See Methods). These mice develop a very mild
form of iris disease due to the Tyrp1b mutation, but do not
develop elevated IOP or glaucoma. These strains further
define the relative contributions of the Tyrp1 and Gpnmb
genes to the D2 phenotype and will serve as powerful con-
trol strains in future studies of glaucoma.
Results
We have developed control strains that will maximize the
potential of D2 mice in understanding the pathogenesis
of both pigment dispersing iris disease and glaucoma. For
the first control strain, named D2.Tyrp1B6GpnmbB6, the
mutated forms of Tyrp1 and Gpnmb were replaced with
wild-type alleles from B6 (Tyrp1B6 and GpnmbB6, see Meth-
ods). Mutations in Tyrp1 alter coat color in various strains
[17]. As a consequence of the Tyrp1B6  allele,
D2.Tyrp1B6GpnmbB6 mice have a darker coat color than D2
mice (Figure 1a). The extent of B6-derived sequence flank-
ing both Tyrp1 and Gpnmb genes in this strain was assessed
using polymorphic markers. For Tyrp1B6, the proximal
breakpoint was mapped to between D4Mit151  and
D4Mit178 and the distal breakpoint to between D4Mit185
and D4Mit146 (Figure 1b). The maximum size of the B6-
derived region flanking Tyrp1B6 is 50 Mb or 1.9% of the
mouse genome. For GpnmbB6, the proximal breakpoint
was mapped to between D6Mit268 and D6Mit207, and
the distal breakpoint to between D6Mit277 and D6Mit16
(Figure 1c). The maximum amount of B6 sequence flank-
ing GpnmbB6 is estimated to be 36 Mb or 1.4% of the
mouse genome.
D2.Tyrp1B6GpnmbB6 show no iris disease, IOP elevation or 
glaucoma
As previously reported, the irides of D2 mice with both
the GpnmbR150X and Tyrp1b mutations develop severe pig-
ment dispersion and iris atrophy (Figure 2a–c). However,
as expected, the irides of D2.Tyrp1B6GpnmbB6 mice appear
totally normal at all ages. IOP elevation is a key risk factor
for glaucoma and occurs in D2 mice as a result of the iris
disease. Typically, a population of D2 mice shows ele-
vated IOP levels that peak at around 9–10 months of age
(Figure 3a). In contrast, IOPs of D2.Tyrp1B6GpnmbB6 mice
are not elevated compared to young mice at any assessed
age (Figure 3b).
D2.Tyrp1B6GpnmbB6 mice were further assessed for optic
nerve damage. The amount of RGC axon damage was
determined using a three point damage rating system
based on the amount of axon damage detected in the ret-
rorbital portion of the optic nerve [10]. This system has
been validated against axon counting [18,19]. 70% of D2BMC Genetics 2007, 8:45 http://www.biomedcentral.com/1471-2156/8/45
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mice have glaucomatous optic nerve damage by 12
months of age (Figure 3c). In contrast,
D2.Tyrp1B6GpnmbB6 show no evidence of glaucomatous
damage at 12 months of age (Figure 3d).
D2.Tyrp1B6GpnmbB6 mice have B6-derived chromosomal
regions (congenic intervals) flanking Tyrp1  and  Gpnmb
respectively. Together, these B6-derived regions represent
up to 3.3% of the genome (Figure 1). To produce an even
more closely matched control strain, we developed D2-
Gpnmb+, a second control strain that has no B6-derived
congenic intervals. To generate the D2-Gpnmb+ strain, the
GpnmbR150X allele of modern day D2 mice was replaced
with the Gpnmb+ allele from the D2-sdy strain (the original
wild-type D2 Gpnmb allele, see Methods).
D2-Gpnmb+ mice develop a mild iris disease
D2-Gpnmb+ mice were aged and assessed for ISA and IPD.
Although wild-type for Gpnmb, D2-Gpnmb+  mice are
homozygous for the Tyrp1b mutation. Therefore, they are
expected to develop the ISA iris disease that is caused by
this mutation. A mild ISA disease is observed in these
mice (Figure 4a–c). The ISA phenotype in D2-Gpnmb+
mice is characterized by a change in iris stromal morphol-
ogy (appearing "roughened" and lacking complexity).
However, the iris shows no evidence of IPD, maintains
integrity, and is overall very mildly affected when com-
pared to the severe, combined ISA and IPD phenotype of
D2 mice.
D2-Gpnmb+ mice do not develop elevated IOP or 
glaucoma
IOP was assessed at a variety of ages between 4 months
and 23 months of age. The selected ages are relevant to the
window of IOP changes observed in DBA/2J mice. There
was no age-related increase of IOP in these mice. Addi-
tionally, no D2-Gpnmb+ mice had IOP values above 21
mmHg, levels considered to be glaucoma-suspect in peo-
ple (Figure 4d). Consistent with this, we detected no signs
of glaucomatous RGC death and optic nerve degeneration
in D2-Gpnmb+ mice. D2 mice show RGC death, loss of the
nerve fiber layer and severe optic nerve cupping by 12
months of age [10]. Retina and optic nerve morphology
was examined in 4 eyes taken from D2-Gpnmb+ mice at
each of 4.5 months, 12 months and 18 months of age
(Figure 5a–c). The RGC layer and nerve fiber layer was
normal, and there was no evidence of optic nerve head
cupping (Figure 5d). Optic nerve damage was further
assessed by sectioning a portion of the retro-orbital optic
nerve and staining with PPD, a stain that sensitively
detects degenerating axons. There was no evidence of
glaucomatous optic nerve damage in D2-Gpnmb+  eyes
taken from a large number of mice between 4.5 and 15
months of age (Figure 5e–i). Importantly, there was no
correlation between optic nerve damage and measured
IOP level in individual mice and thus the range of pres-
sure seen in D2-Gpnmb+ did not affect nerve damage. In
addition, we compared axon number in young pre-glau-
comatous D2 eyes with aged D2-Gpnmb+ eyes, using a pre-
viously described counting system [18,19], and there was
no significant difference in axon number (51,748 ± 907
for D2, and 52,074 ± 427 for D2-Gpnmb+, n = 10 for each
group, p = 0.7). A moderate form of optic nerve damage
was present in one eye from a 12 months old mouse, and
2 eyes from mice over 16 months of age. This may be a
very rare case of glaucoma due to the mutant Tyrp1 gene,
or more likely age-related damage that is not related to
glaucoma as a similar degree of damage is observed in
other non-glaucomatous mouse strains of a similar age
[12,20].
Analysis of D2.Tyrp1B6GpnmbB6 mice Figure 1
Analysis of D2.Tyrp1B6GpnmbB6 mice. A. D2.Tyrp1B6GpnmbB6 mice (right) show a darker coat color compared to D2 mice (left) 
due to the presence of a wild-type Tyrp1 gene. B-C. Regions of B6-derived sequence containing Tyrp1 (B) and Gpnmb (C) are 
indicated by the black horizontal lines, dotted lines indicate the region within which the breakpoints lie. The estimated maxi-
mum sizes of the regions (taken from Ensembl) are indicated. Polymorphic markers flanking the breakpoint regions are shown 
and the orientation of the genes are indicated below.BMC Genetics 2007, 8:45 http://www.biomedcentral.com/1471-2156/8/45
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Discussion
DBA/2J is an established mouse model for inherited glau-
coma that shows iris pigment dispersion, IOP elevation
and optic nerve degeneration. D2 mice are homozygous
for both the GpnmbR150X and Tyrp1b mutations. Both of
these mutations are necessary for the severe iris pigment
disease that leads to IOP elevation and glaucoma [16].
Although DBA/2J is an experimentally tractable model of
glaucoma, it is an inbred mouse strain and so no strain
matched DBA/2J controls without glaucoma have been
available. Here we describe the generation of two deriva-
tive strains of DBA/2J (D2.Tyrp1B6GpnmbB6  and D2-
Gpnmb+), where either the mutant alleles of both Gpnmb
and Tyrp1 or only Gpnmb have been replaced by wild-type
versions. D2.Tyrp1B6GpnmbB6 mice contain a maximum of
3.3% of B6-derived sequence on a D2 background. In the
case of D2-Gpnmb+, the only known difference compared
to D2 is a single base change in the Gpnmb gene. Neither
D2.Tyrp1B6GpnmbB6 nor D2-Gpnmb+ strains develop IOP
elevation or glaucoma.
Since determining that the Gpnmb mutation recently arose
on the DBA/2J background [10], we have produced a fur-
ther control strain, D2.Tyrp1B6Gpnmb+, that is currently
being characterized. This strain contains a congenic inter-
val flanking Tyrp1  but is improved over
D2.Tyrp1B6GpnmbB6 in that it lacks a congenic interval
around Gpnmb (as the Gpnmb+ allele is the ancestral DBA/
2J allele). This strain is wild-type for both glaucoma
inducing genes and is not expected to develop any D2
glaucoma-associated phenotypes. Although characteriza-
tion of large numbers of these mice is a lengthy undertak-
Comparison of iris disease in 13 months old D2 mice and D2.Tyrp1B6GpnmbB6 mice Figure 2
Comparison of iris disease in 13 months old D2 mice and D2.Tyrp1B6GpnmbB6 mice. A and D show broad-beam illumination, B 
and E show transillumination defects and C and F show the relative dimensions of the anterior chamber. A-C. In D2 mice, the 
iris disease involves iris stromal atrophy, transillumination defects and progressive depigmentation with abnormal dispersal of 
iris pigment into the anterior chamber. D-F. In contrast, D2.Tyrp1B6GpnmbB6 mice show no iris pigment disease, transillumina-
tion defects or alteration of the anterior chamber.BMC Genetics 2007, 8:45 http://www.biomedcentral.com/1471-2156/8/45
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Assessment of IOP levels and glaucoma in D2.Tyrp1B6GpnmbB6 mice Figure 3
Assessment of IOP levels and glaucoma in D2.Tyrp1B6GpnmbB6 mice. A. IOP profile of a population of D2 mice (1437 IOPs) 
between 4 and 20 months of age. B. IOP profile of 88 D2.Tyrp1B6GpnmbB6 mice between 6 and 18 months of age. Individual IOP 
measurements are plotted as circles. The horizontal line indicates 21 mmHg, a value considered to be glaucoma-suspect in 
people. IOP elevation above 21 mmHg is first observed in D2 mice at around 6 months of age, and peaks at 9–10 months. 
D2.Tyrp1B6GpnmbB6 mice show no significant IOP elevation above 21 mmHg. C. Previously reported frequencies of optic nerve 
damage in D2 mice are presented showing clear glaucomatous damage. Approximately 70% of D2 eyes have moderate or 
severe damage by 12 months of age, and 80% by 16–19 months of age. D. In contrast no glaucomatous damage was seen in 18 
D2.Tyrp1B6GpnmbB6 eyes at 12 months of age, and only 5% (3 of 39) of eyes from 16–19 months of age had obvious disease. A 
total of 72 eyes were analyzed for all ages. Mild nerves have fewer than 5% damaged axons, moderate (mod) nerves have 
between 5% and 50% axon damage, and severe nerves have greater than 50% axons damaged. Only moderate and severe 
nerves are considered to show glaucomatous damage, as mild damage is frequently observed in aging non-glaucomatous strains 
by 10 to 12 months of age. At 12 months of age, moderate damage is very unusual in non-glaucomatous strains and so we con-
sider this degree of damage a sign of glaucoma. Although moderate damage is not common in non-glaucomatous mice, it does 
occur in more mice of non-glaucomatous strains by 16 to 18 months. Thus, at these older ages, moderate damage may be 
caused by an unusual degree of age-related RGC demise or by glaucoma. The single case of severe damage is extremely rare in 
control mice and may or may not represent glaucoma.BMC Genetics 2007, 8:45 http://www.biomedcentral.com/1471-2156/8/45
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ing, initial analyses agree with the findings reported here
for D2.Tyrp1B6GpnmbB6 mice, with no evidence of iris dis-
ease, IOP elevation or glaucoma.
Regarding the control strains, the following points are per-
tinent. Although they lack all iris disease and glaucoma,
the D2.Tyrp1B6GpnmbB6 strain does not typically repro-
duce as well as the D2-Gpnmb+ strain and appears to have
an increased incidence of early deaths (based on retro-
spective observations, but no specific spontaneous death
study has been conducted). Although not well character-
ized, the decreased fecundity appears to be related to the
Tyrp1B6 allele on a D2 background, since other D2 strains
that we have been producing with this allele have exhib-
ited a similar phenotype. These issues do not prevent the
use of this strain. However, since the D2-Gpnmb+ strain
A-C. Iris disease and IOP in D2-Gpnmb+ mice Figure 4
A-C. Iris disease and IOP in D2-Gpnmb+ mice. A. Broad-beam illumination. B. Transillumination. C. Side view dimensions of 
the anterior chamber. D2-Gpnmb+ eyes show no IPD but have a distinct form of ISA where the iris appears 'roughened'. D2-
Gpnmb+ eyes have no transillumination defects and normal anterior chamber morphology (more than 20 eyes were analyzed 
from a variety of ages, images shown here are from a 13 months old mouse). D. IOP measurements in D2-Gpnmb+ mice. Indi-
vidual IOP readings are plotted as circles. The solid horizontal line indicates 21 mmHg, a value considered to be glaucoma-sus-
pect in people. No 'high' IOP readings were seen in 97 eyes measured. Also, there is no significant change in IOP levels 
comparing 4 months old D2-Gpnmb+ mice to the 8, 10, 12 or 14 months old groups (p > 0.37 for all comparisons).BMC Genetics 2007, 8:45 http://www.biomedcentral.com/1471-2156/8/45
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lacks these issues and has no B6 derived interval, we rec-
ommend it as a control when studying glaucomatous neu-
rodegeneration. Although the D2-Gpnmb+  strain still
develops a mild iris disease, glaucomatous nerve damage
was clearly absent in the vast majority, if not all, of these
mice. Thus, despite the spread in IOP, the highest IOPs
D2-Gpnmb+ mice do not develop glaucoma Figure 5
D2-Gpnmb+ mice do not develop glaucoma. A-C. H&E stained sections of D2-Gpnmb+ mice at 4.5 mo (A), 12 mo (B) and 18 
mo (C) showing a normal nerve fiber layer (arrows) and no evidence of optic nerve cupping. D. H&E section of a 12 months 
old D2 mouse with severe glaucoma, showing optic nerve cupping (asterisk) and loss of nerve fiber layer (arrows). E-G. PPD 
staining of the retro-orbital optic nerve from a 4.5 mos (E), 12 mos (F), 18 mos (G) D2-Gpnmb+ mice. These nerves are 
healthy with only rare degenerating axons, as is typical for nerves of non-glaucomatous mouse strains. H. Severe glaucoma in a 
12 mos D2 eye. Healthy axons have clear axoplasm, surrounded by darkly stained myelin (arrow). The sick or dying axons stain 
grey/black (arrowhead). (I) Frequency of glaucomatous optic nerve damage in D2-Gpnmb+ mice, using the 3 point grading sys-
tem (see Methods). No D2-Gpnmb+ mice show severe glaucoma, and only 3 eyes show moderate damage. Importantly, these 
moderately affected nerves only just enter this grade (all had less than 10% axon loss), and were not as severely degenerated as 
the typical D2 moderate nerve.BMC Genetics 2007, 8:45 http://www.biomedcentral.com/1471-2156/8/45
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were not significant enough to induce glaucomatous axon
loss. When using these control strains, it is important to
remember that they may still have some undefined but
glaucoma relevant phenotype(s).
It is clear that glaucoma is a multifactorial disease and D2
mice are likely to have susceptibility factors in addition to
those associated with the Gpnmb and Tyrp1 genes. Thus,
although these strains do not develop glaucoma, as
defined by the absence of nerve damage, they may still
have other phenotypes that render the D2 background
susceptible to glaucoma. Such phenotypes may or may
not have contributed to nerve the damage detected in a
small percentage of mice.
Tyrp1 and Gpnmb function in melanosomes, organelles
that produce pigment. Manifestation of both IPD and ISA
in D2 eyes is dependent upon active pigment production
[16,20]. The mechanisms involved in IPD and ISA and the
subsequent IOP elevation are complex and in addition to
pigment production appear to involve immunity [21,22].
Ongoing functional mouse genetics experiments comple-
mented with a variety of immunological, molecular and
cellular techniques are vital to unravel these mechanisms.
The control strains described here will be a valuable
resource in elucidating the biological mechanisms
involved in pigment-related iris disease. In addition to
ocular-related diseases, these strains provide an important
resource to test the roles of Tyrp1 and Gpnmb in other dis-
eases. Tyrp1 is the most common melanoma antigen and
Gpnmb is used as a marker for metastatic melanomas [23]
and has recently been identified as a potential molecular
therapeutic target in patients with glioblastoma multi-
forme [24]. Gpnmb may also be important in antigen pre-
senting cells that control immune responses [21].
To improve our understanding of glaucoma, it is essential
that genes and pathways involved in IOP elevation and
glaucomatous RGC and optic nerve degeneration are
identified. By analyzing gene expression profiles in D2
mice at various ages [25], and conducting subsequent
functional tests, it is possible to identify differentially
expressed genes important for the onset and/or progres-
sion of glaucoma. Individual mouse strains, such as D2,
have a unique collection of alleles affecting many biolog-
ical processes and that affect gene expression levels and
protein activity [26]. Therefore, many gene expression dif-
ferences are observed between D2 and other naturally
occurring strains that do not get glaucoma [27]. This can
complicate experiments and make it difficult to prioritize
genes for subsequent functional testing. Additionally, it is
possible that strain differences can mask some expression
changes that occur in D2 mice and are relevant to the glau-
coma. By enabling analysis of age- and strain-matched
control mice, the control strains reported here alleviate
the difficulties of controlling experiments using D2 mice.
Conclusion
The strains describes here will enable the systematic eval-
uation of the processes involved in iris disease, IOP eleva-
tion and glaucoma, work that is likely to provide novel
understanding and lead to targets for improved therapeu-
tics for human glaucomas.
Methods
Animal husbandry and strain development
Mice were housed in a 14 h light to 10 h dark cycle under
previously described conditions [9,15]. The Jackson Labo-
ratory's (Bar Harbor, Maine, United States) pathogen sur-
veillance program regularly screened for pathogens. All
experiments were conducted in accordance with the Asso-
ciation for Research in Vision and Ophthalmology's state-
ment on the use of animals in ophthalmic research and
were approved by our institutional animal care and use
committee. Modern DBA/2J (D2) mice (#000671, see
[28]) have mutations in both Tyrp1 and Gpnmb. Although
the majority of included data for modern D2 mice has
been previously published, over 300 modern D2 mice
were aged and analyzed over the same period of time as
the mice of the other strains presented here. For the gen-
eration of the D2.Tyrp1B6GpnmbB6 strain, D2 mice were
crossed to C57BL/6J (B6) to create F1s. Progeny carrying
the B6 allele of both Gpnmb  (GpnmbB6) and Tyrp1
(Tyrp1B6) were then backcrossed to D2 for ten generations.
Brother/sister matings were then established to generate
mice homozygous for GpnmbB6 and Tyrp1B6 and to main-
tain a stable D2.Tyrp1B6GpnmbB6 doubly homozygous col-
ony.
The GpnmbR150X mutation arose in the early 1980s and
became fixed in the ancestors of modern day D2 mice
[16]. The sdy mutation alters coat color and occurred in
DBA/2J (D2) mice in 1983. At that point, the DBA/2J-
Dtnbp1sdy strain (hereafter referred to as D2-sdy) was sepa-
rated from the main D2 colony. Genotyping a D2-sdy col-
ony for Gpnmb in the early 2000s revealed that these mice
had an original wild-type allele of Gpnmb (Gpnmb+). To
develop the D2-Gpnmb+ strain, D2-sdy  were crossed to
modern D2 mice for three generations. We are continuing
to backcross D2-Gpnmb+ to modern day D2 to further
reduce the possibility of D2-Gpnmb+  mice harboring
unknown genetic differences compared to modern day
D2 mice. These higher generation D2-Gpnmb+ mice will be
provided to the community. (They are being accepted for
distribution by Jackson Laboratory mouse resources and
will become strain DBA/2J-Gpnmb+/SjJ with stock #
007048). However, to hasten characterization of mice
with a D2 genetic background and a wild type allele of
Gpnmb, brother/sister matings that did not carry the sdyBMC Genetics 2007, 8:45 http://www.biomedcentral.com/1471-2156/8/45
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mutation were selected to establish the D2-Gpnmb+ strain
that is homozygous for the wild-type Gpnmb allele and
characterized here. These matings also produced the mice
for clinical examinations, IOP measurements and assess-
ment of glaucomatous damage. Analysis of 102 microsat-
ellite markers (average spacing 13.25 cM) revealed no
allelic differences between D2-Gpnmb+ and modern day
D2.
Genotyping
The GpnmbR150X mutation creates a novel PvuII enzyme
site [16]. DNA isolated from tail snips was used to PCR
amplify the 125 bp region surrounding the mutation
using primers nmb7 (CTACAACTGGACTGCAGGGG)
and nmb8 (AGCTCCATTTCTTCCATCCA). The resulting
product was digested with PvuII (NEB). The presence of
the mutation is indicated by the presence of two bands of
50 bp and 75 bp. Identification of B6-derived sequence
that included Tyrp1  on Chromosome 4 was achieved
using the flanking polymorphic markers D4Mit178 (D2 =
170 bp, B6 = 146 bp) and D4Mit327 (D2 = 92 bp, B6 =
106 bp). Identification of B6-derived sequence that
included Gpnmb on Chromosome 6 was achieved using
the flanking polymorphic markers D6Mit74 (D2 = 150
bp, B6 = 160 bp) and D6Mit355 (D2 = 106 bp, B6 = 124
bp). The extent of the B6-derived region was analyzed
using polymorphic markers spanning Chromosomes 4
and 6 (see [29]).
Clinical examinations
We examined eyes at 2–24 months of age with a slit-lamp
biomicroscope (Haag-Streit) and photographed them
with a 40× objective lens. Phenotypic assessment of iris
stromal atrophy, dispersed pigment and transillumina-
tion was carried out as described previously [9,15,20].
IOP and optic nerve assessment
Mice were acclimatized to the procedure room, anesthe-
tized by using an intraperitoneal injection of ketamine/
xylazine mixture and IOP measured as previously
described [30]. Optic nerve cross sections were examined
for glaucomatous damage using a modified paraphe-
nylenediamine (PPD) staining protocol to stain the mye-
lin sheath of all axons and the axoplasma of damaged
axons as described previously [18]. Optic nerves were
assessed for glaucomatous damage using a non-biased
three point grading system that has been validated against
axon counting [18,19]. Axon counts were carried out as
previously described [18,19]. 10 randomly selected D2
eyes (pre-glaucomatous, 3 to 4 months) and 10 randomly
selected D2-Gpnmb+ eyes (no glaucoma, 10.5 to 11 mos)
were counted.
Histology
Eyes were fixed in 4% paraformaldehyde (PFA) overnight
at 4°C and stored in 0.4% PFA at 4°C. For general mor-
phology, eyes were processed, embedded in plastic, sec-
tioned and stained with Hemotoxylin and Eosin.
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